Skip to main content

Advertisement

SpringerLink
Log in

Hepatic osteodystrophy: Does the osteoprotegerin/receptor activator of nuclear factor-kB ligand systemplay a role?

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Multiple factors can contribute to the development of osteodystrophy in patients with chronic liver disease (CLD). Recently, two new cytokines, osteoprotegerin (OPG) and the receptor activator of nuclear factor-kB ligand (RANKL), have been implicated in the pathogenesis of post-menopausal osteoporosis and other metabolic bone diseases. Therefore, the aim of our study was to evaluate bone metabolism, bone mineral density (BMD) and OPG/RANKL system in 65 male patients with CLD and in 65 healthy controls. Our patients showed lower BMD values than controls both at lumbar and femoral levels. Moreover, they had an unbalanced bone turnover with an increased resorption phase, as shown by high levels of urinary deoxypyridinoline and a decreased formation phase, as shown by the slightly, but significant, low levels of bone-alkaline phosphatase. Patients showed lower plasma levels of free-testosterone than controls and higher—although not significantly so—plasma levels of 17 β-estradiol. Furthermore, patients with CLD had higher levels of sex hormone-binding globulin and OPG, and lower levels of 25-hydroxyvitamin D (25-HOD)and IGF-I than the control group, while RANKL levels were similar in the two groups. In conclusion, our data do not confirm the hypothesis that the OPG/RANKL system could exert a key role in the pathogenesis of hepatic osteodystrophy, but rather that the observed increase in OPG levels may represent either the result of the inflammatory process per se or a compensation for the observed enhanced bone resorption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S. Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 1989, 96: 213–21.

    PubMed  CAS  Google Scholar 

  2. Diamond Th, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990, 31: 82–7.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  3. Rose J, Compston JE, Crawley EO, Evans W, Evans C, Smith P. Osteoporosis associated with chronic liver disease. Eur J Gastroenterol Hepatol 1991, 3: 63–9.

    Google Scholar 

  4. Bonkovsky HL, Hawkins M, Steinberg K, et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990, 12: 273–80.

    Article  PubMed  CAS  Google Scholar 

  5. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001, 33: 301–7.

    Article  PubMed  CAS  Google Scholar 

  6. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev 1992, 13: 66–80.

    PubMed  CAS  Google Scholar 

  7. Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev 1996, 17: 308–32.

    PubMed  CAS  Google Scholar 

  8. Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997, 12: 869–79.

    Article  PubMed  CAS  Google Scholar 

  9. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89: 309–19.

    Article  PubMed  CAS  Google Scholar 

  10. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95: 3597–602.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  11. Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000, 85: 2355–63. au12._World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. W. H. O. Technical Report Series 1994, 843.

    PubMed  CAS  Google Scholar 

  12. Ormarsdottir S, Ljunggren O, Mallmin H, Brahm H, Loof L. Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol 1999; 31: 84–90.

    Article  PubMed  CAS  Google Scholar 

  13. Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994, 9: 1515–23.

    Article  PubMed  CAS  Google Scholar 

  14. Crosbie OM, Freaney R, McKenna MJ, Hegarty JE. Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. Calcif Tissue Int 1999, 64: 295–300.

    Article  PubMed  CAS  Google Scholar 

  15. Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone 1995, 17(Suppl 2): 93S–8S.

    Article  PubMed  CAS  Google Scholar 

  16. Hattori N, Urahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M. Serum growth hormone-binding protein, insulin-like growth factor-1 and growth hormone in patients with liver cirrhosis. Metab Clin Exp 1992, 41: 377–81.

    Article  PubMed  CAS  Google Scholar 

  17. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mun-di JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998, 28: 695–9.

    Article  PubMed  CAS  Google Scholar 

  18. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrin Rev 1995, 16: 3–34.

    CAS  Google Scholar 

  19. Duarte MP, Farias ML, Coelho HS, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001, 16: 1022–7.

    Article  PubMed  CAS  Google Scholar 

  20. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995, 108: 276–83.

    Article  PubMed  CAS  Google Scholar 

  21. Arnaud SB. 25-Hydroxyvitamin D treatment of bone disease in primary biliary cirrhosis. Gastroenterology 1982; 83: 137–9.

    PubMed  CAS  Google Scholar 

  22. Hay JE, Lindor KD, Weisner RH, Dickson ER, Krom RAF, LoRusso LF. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991, 14: 257–61.

    Article  PubMed  CAS  Google Scholar 

  23. Hodgson SF, Dickson ER, Weisner RH, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985, 103: 855–60.

    Article  PubMed  CAS  Google Scholar 

  24. Bell H, Raknerud N, Falch JA, Haug E. Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis. Eur J Endocrinol 1995, 132: 444–9.

    Article  PubMed  CAS  Google Scholar 

  25. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Growley WF. Osteoporosis in men with idiopathic hypogonadotrophic hypogonadism. Ann Intern Med 1987, 106: 354–61.

    Article  PubMed  CAS  Google Scholar 

  26. Biller BMK, Saxe V, Herzog DB, Rosenthal DI, Holzman S, Klibanski A. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin Endocrinol Metab 1989, 68: 548–54.

    Article  PubMed  CAS  Google Scholar 

  27. Kaymakoglu S, Okten A, Cakaloglu Y, et al. Hypogonadism is not related to the etiology of liver cirrhosis. J Gastroenterol 1995, 30: 745–50.

    Article  PubMed  CAS  Google Scholar 

  28. Pignata S, Daniele B, Galati MG, et al. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1997, 9: 283–6.

    Article  PubMed  CAS  Google Scholar 

  29. Lindholm J, Fabricius-Bjerre N, Bahnsen M, Boiesen P, Hagen C, Christensen T. Sex steroids and sex-hormone binding globulin in males with chronic alcoholism. Eur J Clin Invest 1978, 8: 273–6.

    Article  PubMed  CAS  Google Scholar 

  30. Lormeau C, Soudan B, d’Herbomez M, Pigny P, Duquesnoy B, Cortet B. Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis. Bone 2004, 34: 933–99.

    Article  PubMed  CAS  Google Scholar 

  31. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332: 305–11.

    Article  PubMed  CAS  Google Scholar 

  32. Pacifici R. Estrogen, cytokines, and pathogenesis of postmen-opausal osteoporosis. J Bone Miner Res 1996, 11: 1043–51.

    Article  PubMed  CAS  Google Scholar 

  33. Spelsberg TC, Subramaniam M, Riggs BL, Khosla S. The actions and interactions of sex steroids and growth factors/ cytokines on the skeleton. Mol Endocrinol 1999, 13: 819–28.

    Article  PubMed  CAS  Google Scholar 

  34. Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997, 234: 137–42.

    Article  PubMed  CAS  Google Scholar 

  35. HakedaY, Kobayashi Y, Yamaguchi K, et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun 1998, 251: 796–801.

    Article  Google Scholar 

  36. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitoryfactor/osteoprotegerin. Biochem Biophys Res Commun 1998, 247: 610–5.

    Article  PubMed  CAS  Google Scholar 

  37. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991, 13: 267–76.

    Article  PubMed  CAS  Google Scholar 

  38. Hegedus D, Ferencz V, Lakatos PL, et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res 2002, 17: 1961–7.

    Article  PubMed  CAS  Google Scholar 

  39. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999, 14: 518–7.

    Article  PubMed  CAS  Google Scholar 

  40. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140: 4367–70.

    PubMed  CAS  Google Scholar 

  41. Saika M, Inoue D, Kido S, Matsumoto T. 17ß-Estradiol stimulates expression of osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) by a mouse stromal cell line, ST-2. J Bone Miner Res 1999, 14(Suppl 1): F095.

    Google Scholar 

  42. Szalay F, Hegedus D, Lakatos PL, et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 2003, 38: 395–400.

    Article  PubMed  CAS  Google Scholar 

  43. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001, 86: 3162–5.

    PubMed  CAS  Google Scholar 

  44. Rubin J, Ackert-Bicknell CL, Zhu L, et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 2002, 87: 4273–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Messina, Messina, Italy

    A. Gaudio, A. Lasco, N. Morabito, M. Atteritano, C. Vergara, A. Catalano, W. Fries, A. Trifiletti & N. Frisina

Authors
  1. A. Gaudio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Lasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Morabito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Atteritano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Vergara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Catalano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Fries
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Trifiletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N. Frisina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Gaudio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gaudio, A., Lasco, A., Morabito, N. et al. Hepatic osteodystrophy: Does the osteoprotegerin/receptor activator of nuclear factor-kB ligand systemplay a role?. J Endocrinol Invest 28, 677–682 (2005). https://doi.org/10.1007/BF03347549

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347549

Keywords

Search

Navigation